Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 3/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 3/20 | 0.38 |
| ▸ | CDK9 | P50750 | 3/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.37 |
| ▸ | QPCT | Q16769 | 2/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6956508 | 0.91 | CCNT1 (0.42) | GSK3BCCNT1CDK9QPCTCCNA2 | |
| SCHEMBL6956384 | 0.86 | CCNT1 (0.46) | CCNT1CDK9CCNA2CDK2 | |
| SCHEMBL6954265 | 0.86 | CDK9 (0.39) | GSK3BCCNT1CDK9CCNA2CDK2 | |
| SCHEMBL7500940 | 0.83 | CCNT1 (0.46) | GSK3BCCNT1CDK9CCNA2CDK2 | |
| SCHEMBL6951202 | 0.83 | CCNT1 (0.43) | CCNT1CDK9CCNA2CDK2 | |
| SCHEMBL7164524 | 0.83 | CCNT1 (0.47) | CCNT1CDK9CCNA2CDK2 | |
| SCHEMBL6947835 | 0.81 | CCNT1 (0.44) | CCNT1CDK9CCNA2CDK2 | |
| SCHEMBL6946616 | 0.81 | CCNT1 (0.45) | CCNT1CDK9CCNA2CDK2 | |
| SCHEMBL7508601 | 0.80 | CCNT1 (0.47) | CCNT1CDK9CCNA2CDK2 | |
| SCHEMBL6954175 | 0.80 | CCNT1 (0.43) | CCNT1CDK9CCNA2CDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1155595-C | Substituted pyrroles as antiproliferative agents for the treatment of cancer | - | 2004-06-30 | — | — | CN | disclosed |
| EP-1224181-B1 | SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | HOFFMANN LA ROCHE (CH) | 2003-12-03 | — | — | EP | disclosed |
| US-6559164-B1 | These compounds and their pharmaceutically acceptable salts are suitable for administration to patients as continuous infusion solution and are useful in the treatment and/or control of cell proliferative disorders, in particular cancer. | HOFFMANN-LA ROCHE INC. | 2003-05-06 | — | — | US | disclosed |
| CN-1378545-A | Substituted pyrroles as antiproliferative agents for treatment of cancer | HOFFMANN LA ROCHE (CH) | 2002-11-06 | — | — | CN | disclosed |
| EP-1224181-A1 | SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-24 | — | — | EP | disclosed |
| WO-2001027106-A1 | SUBSTITUTED PYRROLES AS ANTIPROLIFERATIVE AGENTS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2001-04-19 | — | — | WO | disclosed |